{"id":1079,"date":"2023-08-25T14:20:24","date_gmt":"2023-08-25T14:20:24","guid":{"rendered":"https:\/\/blogs.bmj.com\/rheumsummaries\/?p=1079"},"modified":"2023-08-25T14:20:24","modified_gmt":"2023-08-25T14:20:24","slug":"can-anti-rheumatic-treatments-deliver-cardiovascular-protection","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/rheumsummaries\/2023\/08\/25\/can-anti-rheumatic-treatments-deliver-cardiovascular-protection\/","title":{"rendered":"Can anti-rheumatic treatments deliver cardiovascular protection?"},"content":{"rendered":"

People with rheumatoid arthritis have increased arterial inflammation that is responsive to effective treatments<\/span>
\n<\/span><\/p>\n

Introduction<\/strong><\/b><\/p>\n

Rheumatoid arthritis is a chronic inflammatory disease that mainly affects a person\u2019s joints, causing pain and disability among other symptoms. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and 60. It is more common in women than men.\u00a0<\/span><\/p>\n

The same inflammation that drives rheumatoid arthritis can also cause cardiovascular disease \u2013 also called heart disease. Cardiovascular disease is a general term for conditions that affect the heart or blood vessels. It leads to narrowed arteries and an increased risk of cardiovascular events, such as heart attacks or strokes. On average, people with rheumatoid arthritis have a 50% increased risk of these events compared to people in the general population.\u00a0<\/span><\/p>\n

Recent trials have shown that treatments that dampen the underlying inflammation reduce the number of cardiovascular events that happen in people with cardiovascular disease. But there is limited information about whether these treatments can also prevent cardiovascular events in people with rheumatoid arthritis.\u00a0<\/span><\/p>\n

What did the authors hope to find?<\/strong><\/span><\/p>\n

The authors wanted to see whether specific treatment strategies that are used for rheumatoid arthritis would reduce people\u2019s cardiovascular risk.<\/span><\/p>\n

Who was studied?<\/strong><\/span><\/p>\n

The study looked at 115 people with active rheumatoid arthritis. Everyone had received methotrexate as their first treatment for rheumatoid arthritis, but they had not been able to achieve adequate control of their disease with this therapy. <\/span>
\n<\/b>
\n<\/b>How was the study conducted?<\/strong><\/span><\/p>\n

This was an open-label, randomised clinical trial, which means that patients were assigned by chance to one of two treatment groups. Using chance in this way means the groups are similar and allows the treatments to be compared objectively. During the treatment both patients and their doctors knew which group they were in.<\/span><\/p>\n

The first group were given a type of medicine called a TNF inhibitor (either etanercept or adalimumab) in addition to their methotrexate.. The second group were given so-called <\/span>triple therapy<\/span><\/i>, with hydroxychloroquine and sulfasalazine added to their methotrexate. These two different treatment strategies were continued for 24 weeks.\u00a0<\/span><\/p>\n

People\u2019s cardiovascular risk was assessed using a heart imaging technique that can show arterial inflammation and correlates well with cardiovascular events. This was measured at the start of the study, and after 24 weeks. Blood tests were also done to see if people had markers that are known to relate to cardiovascular risks. Finally, information about rheumatoid arthritis disease severity was collected.\u00a0 <\/span>
\n<\/span>
\n<\/span>What was the main finding?<\/strong><\/span><\/p>\n

The main finding was that cardiovascular risk was reduced in both treatment groups between the start and end of the study. Overall, the two different treatment approaches had about the same effect on arterial inflammation, with about a 7\u20139% reduction in the arterial signal, a similar amount that is observed with treatments known to reduce cardiovascular events.<\/span><\/p>\n

While rheumatoid disease activity was significantly reduced across both treatment groups, there was no association between this and change in arterial inflammation.\u00a0<\/span><\/p>\n

Are these findings new?<\/strong><\/span><\/p>\n

Yes, until now, nobody has studied the effect of these two treatment strategies on cardiovascular risk in a head-to-head to trial like this one.<\/span><\/p>\n

What are the limitations of this study?<\/strong><\/span><\/p>\n

This was an open-label study, which means that everyone taking part knew what drugs they were using. In some studies, this can cause bias in the results. However, the experts assessing the arterial inflammation were not aware of treatments, so the open-label design should not have affected the results collected.\u00a0<\/span><\/p>\n

Another limitation is that the study did not collect information on actual cardiovascular events, just arterial inflammation.<\/span><\/p>\n

What do the authors plan to do with this information?<\/strong><\/span><\/p>\n

The authors are currently trying to work out how to best assess the cardiovascular risk of people with rheumatoid arthritis, and which biomarkers might be useful<\/span><\/p>\n

What does this mean for me?<\/strong><\/p>\n

If you have rheumatoid arthritis this study is good news, as it shows that treatments that work for your arthritis to reduce pain and disability could also reduce your cardiovascular risk. It is therefore important to find what works for you and stick with it.<\/span><\/p>\n

If you have any concerns about your disease or its treatment, you should talk to your doctor or a healthcare professional involved in your care.<\/span><\/p>\n

Disclaimer:<\/strong> This is a summary of a scientific article written by a medical professional (\u201cthe Original Article\u201d). The Summary is written to assist non medically trained readers to understand general points of the Original Article. It is supplied \u201cas is\u201d without any warranty. You should note that the Original Article (and Summary) may not be fully relevant nor accurate as medical science is constantly changing and errors can occur. It is therefore very important that readers not rely on the content in the Summary and consult their medical professionals for all aspects of their health care and only rely on the Summary if directed to do so by their medical professional. Please view our full Website Terms and Conditions<\/a>.<\/p>\n

Date prepared: <\/strong>July 2023
\nSummary based on research article published on: <\/strong>February 10, 2023
\nFrom: <\/strong>Summary from Solomon DH, et al. Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. <\/span>Ann Rheum Dis 2023;82(x):x\u2013x.<\/span> doi:10.1136\/ard-2022-223302<\/span><\/p>\n

Copyright \u00a9 2023 BMJ Publishing Group Ltd & European League Against Rheumatism. Medical professionals may print copies for their and their patients and students non commercial use. Other individuals may print a single copy for their personal, non commercial use. For other uses please contact our Rights and Licensing Team<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"

People with rheumatoid arthritis have increased arterial inflammation that is responsive to effective treatments Introduction Rheumatoid arthritis is a chronic inflammatory disease that mainly affects a person\u2019s joints, causing pain and disability among other symptoms. Rheumatoid arthritis can affect people of all ages, but it most often starts between the ages of 40 and 60. […]<\/p>\n

Read More…<\/a><\/p>\n","protected":false},"author":467,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6],"tags":[],"class_list":["post-1079","post","type-post","status-publish","format-standard","hentry","category-rheumatoid-arthritis"],"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/posts\/1079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/users\/467"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/comments?post=1079"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/posts\/1079\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/media?parent=1079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/categories?post=1079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/rheumsummaries\/wp-json\/wp\/v2\/tags?post=1079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}